Stock Evaluator: Aspen Pharmacare Holdings Limited (APNHY)
Aspen Pharmacare Holdings Limited APNHY
$8.89
-0.10
-1.06%
July 31, 2026 2:39:58 PM
EST
Volume: 101
After Hours: $120.37
0.15
|
0.12%
November 10, 2021 7:59 PM
EST
Volume: 72,713
USD
| DELAYED PRICE
| SECTOR | INDUSTRY |
| Health Care | Pharmaceuticals |
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Aspen Pharmacare Holdings Limited, together with its subsidiaries, manufactures and markets specialty and branded pharmaceutical products in Africa, the Middle East, the Americas, Europe CIS, Australasia, and Asia. It operates through Commercial Pharmaceuticals and Manufacturing segments. The company offers injectables for therapeutic areas, such as anaesthetics, anticoagulants, antithrombotic agents, analgesics, and hormone replacement medicines under the Arixtra, Diprivan, Fraxiparine, Marcaine, Sustanon, and Xylocaine brands; over-the-counter medicines under the Emla, Maltofer, Ovestin, Solpadeine, and Xylocaine brands; and prescription products for anti-inflammatories, immunosuppressants, hypothyroidism, anti-gout, analgesics, and corticosteroids under the Eltroxin, Imuran, Lipitor, Lyrica, and Zyloric brands. It also manufactures active pharmaceutical ingredients, finished dose forms, and heparins, as well as steriles, oral solid doses, liquids, semi-solids, and biologicals. The company exports its products. Aspen Pharmacare Holdings Limited was founded in 1850 and is headquartered in Durban, South Africa.
Financial Summary
| Share Statistics | APNHY | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $4,001.2 | $579.1 | 64% |
|
| Shares Out (Mil) | 26.9 | 43.0 | 35% |
|
| Institutional Ownership | 38.4% | 84.3% | 16% |
|
| Float (Mil) | 366.1 | 46.8 | 82% |
|
| Beta | 0.34 | 0.62 | 19% |
|
| Avg Daily Volume (000s) | 1 | 285 | 4% |
|
| Price Change (52-week) |
(29.2%) | 63.8% | 25% |
|
| Growth | APNHY | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | 4.7% | 6.7% | 35% |
|
| Net Income (5yr) | (17.4%) | (1.4%) | 23% |
|
| EPS (5yr) | (17.4%) | 14.9% | 16 |
|
| Dividends (5yr) | 0.0% | 0.0% | 58% |
|
| Cash Flow (5yr) | (9.5%) | (14.9%) | 59% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | na | na | na | |
| Current EPS | na | na | na | |
| Month Ago EPS | na | na | na | |
| # Rev Up | na | na | na | |
| # Rev Down | na | na | na | |
| Three Months Ago EPS | na | na | na | |
| Year/Year Chg | na | na | na | |
| Financials | APNHY | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $2,572 | $272 | 64% |
|
| Net Income (TTM) (Mil) | ($121) | ($11) | 9% |
|
| EPS (TTM) | ($0.272) | ($0.500) | 32% |
|
| Operating Cash Flow (TTM) (Mil) | $419 | ($6) | 69% |
|
| Net Cash Flow (TTM) (Mil) | ($8) | $4 | 32% |
|
| Long-Term Debt (Q1) (Mil) | $1,772 | $7 | 73% |
|
| Enterprise Value (Q1) (Mil) | $5,430 | $522 | 64% |
|
| Valuation | APNHY | Industry Median |
Percentile (All Stocks) |
|
| P/B | na | 2.73 | na |
|
| P/E | na | 20.5 | na |
|
| Dividend Yield | na | 0.0% | na |
|
| PEG (5yr hist) | na | 1.2 | na |
|
| Ratios | APNHY | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | 43.0% | 65.9% | 53% |
|
| Net Margin | (4.7%) | 0.7% | 25% |
|
| ROA | (1.6%) | (24.6%) | 35% |
|
| ROE | (2.6%) | (19.7%) | 33% |
|
| Liabilities to Assets | 36.7% | 35.5% | 27% |
|
| F-Score | na | 3 | na |
|
Aspen Pharmacare Holdings Limited did not pass any screens on 7/31/2026.